Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
Retrieved on:
Monday, March 21, 2022
Company, NASDAQ, Boston University, Montgomery, Chairperson, Ruti, Board, Alpha Sigma Tau, Physician, MACA, Kidder, Peabody & Co., Research, Montgomery Securities, Neoplasm, CEO, Economics, Board of directors, Hebrew University of Jerusalem, Eleazar Sukenik, LLC, Technology, Industry, Knowledge, Goal, Alpha, Nasdaq, Surgeon, R, IATI, Columbia University School of General Studies, Patient, Pharmaceutical industry, Pitango, Tel Aviv University
JERUSALEM, March 21, 2022 /PRNewswire/ --Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately.
Key Points:
- JERUSALEM, March 21, 2022 /PRNewswire/ --Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately.
- "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau.
- Ruti Alon added, "I have been following Alpha Tau from its inception, always believing in the technology and its potential.
- Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.